### SARS-Cov-2 Viral Load as an Indicator for COVID-19 Patients' Hospital

2 Stay

1

5

- Salman Al Ali<sup>1</sup>, AbdulKarim AbdulRahman<sup>2</sup>, Omar Yaghi<sup>3</sup>, Essam M. Janahi<sup>4</sup>, Manaf Al-3
- Oahtani<sup>1, 5, 6,\*</sup> 4
- 6 **Short title** Viral load and length of hospital stay
- 7 <sup>1</sup>Bahrain National Taskforce to Combat COVID-19, Bahrain Defense Force Hospital, Bahrain.
- <sup>2</sup>Bahrain National Taskforce to Combat COVID-19, Mohammed bin Khalifa Cardiac Centre, 8
- 9 Bahrain.
- <sup>3</sup>Bahrain National Taskforce to Combat COVID-19, Bahrain. 10
- 11 <sup>4</sup> Independent Researcher, Building 1848, Road 7542, Al Janabiyah 0575, Northern Governorate,
- Bahrain. 12
- <sup>5</sup>Consultant Infectious disease and clinical microbiologist, Bahrain Defense Force hospital, 13
- 14 Bahrain.

16

17

23

24

- <sup>6</sup>Associate Professor in Microbiology at Royal College of Surgeons in Ireland, Bahrain. 15
- \*Corresponding author: 18
- 19 Manaf M. Al-Qahtani
- Consultant Infectious disease and clinical microbiologist, Bahrain Defense Force hospital, 20
- 21 Bahrain
- Email: mgahtani@rcsi-mub.com 22

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

**Abstract Background/objective:** The novel coronavirus disease 2019 (COVID-19) pandemic poses a global threat to the public health. There is a challenge in measuring the patient's length of hospital stay and managing the healthcare resources to handle the situation successfully. Our objective is to use the qPCR cycle of threshold (Ct) as a tool in evaluating the severity of the infection and hence the length of hospital stay to better utilize and manage the healthcare resources. **Methods:** This cross sectional study was carried out on 306 patients who admitted to COVID-19 care centers in Kingdom of Bahrain from 20th March 2020 to 5th April 2020. Standard qPCR was used to estimate the viral load and data were analyzed to investigate the relationship between Ct values and various variables. **Results:** Out of 306 patients, 2 deaths, 1 active stable case and 303 recovered cases were reported. Ct value was significantly and negatively associated (P value < 0.001) with length of hospital stay. The viral clearance was also inversely associated with the Ct values. **Conclusion:** Ct value was inversely associated with hospital stay duration (and time to viral clearance), higher the Ct value is indicative of faster time to viral clearance. This association could help to better manage the infection and resources allocation. **Keywords:** COVID-19; SARS-CoV-2; cycle of threshold; viral clearance; length of hospital stay

### Introduction

Coronavirus disease 2019 (COVID-19) is caused by the newly identified strain of the Coronavirus family Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) <sup>1</sup>. Whilst some patients may have mild symptoms, others develop a severe respiratory distress syndrome with features of a blood coagulopathy requiring intensive support <sup>2</sup>. As a result, COVID-19 has rapidly evolved into a pandemic that has put a severe burden on the healthcare services of some countries, notably beds for both hospitalization and intensive care facilities <sup>3</sup>. Testing aids case identification, case isolation and contact tracing, all of which are vital to limit coronavirus spread 4. Currently, the main diagnostic test for SARS-CoV-2 is the real-time Reverse Transcription Polymerase Chain Reaction (RT-PCR) <sup>5</sup>. The RT-PCR result is influenced by the Cycle Threshold (Ct-Value) that has been suggested as a quantitative test to indirectly assess the viral load <sup>6</sup> with severe cases having a much higher viral load than mild cases <sup>7</sup>. Therefore, the aim of this study was to measure the viral load determined by the Ct value and relate that to viral clearance to determine if this could predict length of hospital stay, as that may help guide

#### Methods

#### **Patients and Sample Collection**

healthcare resource allocation.

A cross sectional study was undertaken on 306 patients who were admitted to COVID-19 care centers in the Kingdom of Bahrain between March 20<sup>th</sup>, 2020 and April 5<sup>th</sup>, 2020. Of those 306 patients, 303 had recovered from their COVID-19 disease. Data were recorded for demographics, Ct-value on admission, time to viral clearance, and data on the length of stay and patient outcomes. At the time of the study, the local protocol in Bahrain admits all positive cases to treatment/isolation facilities regardless of being symptomatic or asymptomatic. The patients are discharged when they have two negative nasopharyngeal and oropharyngeal swabs on two consecutive days. All admitted patients are tested after three days of being asymptomatic and, if negative, the test is repeated after 24 hours to confirm viral clearance, following which the patients are discharged. Therefore, the length of stay was the same as the time to viral clearance and the minimum stay of patients is four days.

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

RNA Extraction and SARS-Cov-2 RNA Amplification The diagnostic test used for SARS-CoV-2 was performed using qPCR on nasopharyngeal and oropharyngeal samples. The samples were transferred to a viral transport media immediately after collection and transported to a COVID-19 laboratory for testing. Diagnosed cases were a heterogeneous sample of tested patients, they included symptomatic and asymptomatic individuals with recent exposure to a confirmed COVID19 case or travelers arriving from high risk countries. PCR test was conducted using Thermo Fisher Scientific (Waltham, MA) TaqPath 1-Step RT-qPCR Master Mix, CG on the Applied Biosystems (Foster City, CA) 7500 Fast Dx RealTime PCR Instrument. The assay used followed the WHO protocol from Charité Virology, Berlin, Germany <sup>8</sup>. and targeted the E gene. If the E gene was detected, the sample was then confirmed by RdRP and N genes. The E gene CT value was reported and used in this study. CT Values >40 were considered negative. Positive and negative controls were included for quality control purposes. **RT-qPCR** Analytical Validation Linear range was determined using serial log<sub>10</sub> dilutions of standard RNA and was established between 3.5 x 10<sup>3</sup> to 3.5 x 10<sup>12</sup> copies of RNA/mL, with amplification efficiency of 87% and with a regression  $R^2$  value higher than 0.99. **Statistical Analysis** Categorical parameters were expressed as frequencies (%), whereas continuous variables are presented as mean. Data trends were visually and statistically evaluated for normality. We used regression analysis to describe the relationship between categorical variables and between continuous variables with the main outcome. Two-way Student's t test was then used to detect the difference between Ct values across symptomatic and asymptomatic individuals. Statistical analysis was performed using STATA statistical computer package (StataCorp. 2013. Stata Statistical Software). **Ethical Approval** The protocol and manuscript for this study were reviewed and approved by the National COVID-

19 Research and Ethics Committee in Bahrain (Approval code: CRT-COVID2020-004). This

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

committee has been jointly established by the Ministry of Health and Bahrain Defense Force Hospital research and ethical committees in response to the pandemic, to facilitate and monitor COVID-19 research in Bahrain. All methods and retrospective analysis of data was approved by the National COVID-19 Research and Ethics Committee, and carried out in accordance with the local guideline and ethical guidelines of the Declaration of Helsinki 1975. Informed consent was waived by the National COVID-19 Research and Ethical Committee for this study due to its retrospective and observational nature and the absence of any patient identifying information **Results** Of the 306 patients, there were 303 who had recovered, whilst 2 deaths and 1 active stable case were excluded from the analysis. The descriptive summary of the patients is shown in Table 1. The sample of patients included cases who arrived in Bahrain from other countries, all travelers being tested upon arrival, and included cases of local spread. Initially, gender distribution of COVID-19 cases in Bahrain was equal; however, as the infection started to spread within the community of labor workers, who are mainly males, the ratio of males to females and the ratio of local cases to cases coming from other countries increased. Symptomatic patients were 12.2% of the sample, which corresponded to a similar percentage of the symptomatic patients in the entire population. Ct values showed a statistically significant negative correlation of 0.28 with the length of hospital stay and time to viral clearance as seen in Figure 1 showing the Lowess smoothing curve of hospital stay. Higher Ct values on admission predicted shorter hospital stays and shorter time to clear the virus. The regression analysis showed similar results when using a univariate analysis and a multivariate analysis adjusted for age and gender. Ct value had a significant inverse correlation with the length of stay, 10 points higher on the Ct value correlating with a shorter hospital stay of 2.8 days. Patients with high Ct values defined as  $\geq$ 35 had shorter hospital stays, by 4.3 days, when compared to patients with Ct values <35 on admission. The regression analysis for Length of Stay using Ct value as a covariate is shown in Table 2. Analysis on symptomatic individuals showed that symptomatic individuals have a lower mean Ct value when compared to asymptomatic individuals. Asymptomatic individuals had a mean Ct

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

value of 27.8. Symptomatic individuals had a mean Ct value of 25.5. A Two sample T-test showed a difference of 2.58 units in the mean Ct value between symptomatic and asymptomatic patients (Table 3). **Discussion** This study has shown that the higher the Ct values, the more rapid the viral clearance, leading to a shorter length of stay in hospital. A Ct value >35 predicted a shorter hospital stay by 4.3 days, and a 10 unit increase in Ct value was associated with a shortened time to viral clearance of 2.8 days. Ct values have been reported as an indirect assessment of the viral load <sup>6,7</sup>, with higher Ct values having a lower viral load, and it has been shown that those patients with more severe disease have lower Ct values <sup>7</sup>. Higher Ct values indicate an early infection or a recovering infection. Whilst Ct values can be used to predict length of hospital stay for stable cases, the Ct value cannot, however, predict outcomes. Outcomes are influenced by many additional predictors, most notably comorbidities and severity of disease <sup>9</sup>. The presence of age greater than 60 and comorbidities including diabetes, hypertension, obesity and respiratory disease may offset a high Ct values and further studies to predict outcomes based on Ct value taking into account adverse risk factors of disease severity are needed. In this study, symptomatic individuals had lower Ct values whilst asymptomatic individuals had higher Ct values, suggesting that the lower Ct values reflects a more severe presentation. However, asymptomatic individuals still had a low mean Ct values (27.8) indicating a significant viral load, suggesting that asymptomatic individuals can still transmit the disease <sup>10</sup>. These results are in accord with those of Liu et al who reported that the mean viral load of severe cases was around 60 times higher than that of mild cases <sup>7</sup>. La Scola et. al have reported using cell culture system that patients with Ct values >= 34 do not shed infectious virions, and hence are not infectious and can be discharged from hospitals or care centers<sup>11</sup>. Bahrain has pursued a comprehensive testing program with all travelers arriving in the country being tested, mobile screening services, random screening in high risk communities and extensive contact tracing. This strategy has resulted in detecting many asymptomatic patients, in contrast to other countries where the response has been directed solely towards symptomatic patients, and has generated data that is critical for production of accurate prediction models <sup>12</sup>.

Limitations of this study include that it was cross sectional and that the number of symptomatic cases were few in number. The number of patients with multiple comorbidities were few and therefore a model to take into account the protective effect of a high Ct value could not be determined. **Conclusion** In this current study it was evident that Ct value can predict the duration of hospital stay of COVID-19 infected patients, which also suggests that viral clearance will be faster in higher Ct value patients. This data can be implemented in other country to evaluate the patients stay at hospital and also helpful in managing the healthcare staff in successfully handling the COVID-19 infected patients. **DECLARATIONS Ethics approval and consent to participate:** The study was approved by the National Covid-19 Research and Ethics Committee.

Consent for publication: Consent for publication was waived by the Ethical committee.

Availability of data and materials: All the data for this study will be made available upon reasonable request to the corresponding author.

Funding: No funding was received to perform this study.

Conflict of interest: The authors have declared that no conflict of interest exists.

Author contributions: SA, and OY analyzed the data and wrote the manuscript. AA, OY and SA contributed to study design, collected, analysed, and interpreted data and edited the manuscript. MA supervised data collection, data analysis and edited the manuscript. EMJ data interpretation and the editing of the manuscript. All authors reviewed and approved the final version of the manuscript. Manaf Alqahtani is the guarantor of this work.

#### References

203

238

239

240

- 204 1. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease
- 205 (COVID-19) outbreak. *Journal of autoimmunity*. May 2020;109:102433.
- 206 doi:10.1016/j.jaut.2020.102433
- 207 2. Fogarty H, Townsend L, Ni Cheallaigh C, et al. COVID-19 Coagulopathy in Caucasian
- patients. British journal of haematology. Apr 24 2020;doi:10.1111/bjh.16749
- 209 3. Carenzo L, Costantini E, Greco M, et al. Hospital surge capacity in a tertiary emergency
- referral centre during the COVID-19 outbreak in Italy. *Anaesthesia*. Apr 4
- 211 2020;doi:10.1111/anae.15072
- 4. Hellewell J, Abbott S, Gimma A, et al. Feasibility of controlling COVID-19 outbreaks by
- 213 isolation of cases and contacts. *The Lancet Global health*. Apr 2020;8(4):e488-e496.
- 214 doi:10.1016/s2214-109x(20)30074-7
- 215 5. Udugama B, Kadhiresan P, Kozlowski HN, et al. Diagnosing COVID-19: The Disease
- and Tools for Detection. *ACS nano*. Apr 28 2020;14(4):3822-3835.
- 217 doi:10.1021/acsnano.0c02624
- 218 6. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 Viral Load in Upper Respiratory
- 219 Specimens of Infected Patients. The New England journal of medicine. Mar 19
- 220 2020;382(12):1177-1179. doi:10.1056/NEJMc2001737
- 221 7. Liu Y, Yan LM, Wan L, et al. Viral dynamics in mild and severe cases of COVID-19.
- 222 The Lancet Infectious diseases. Mar 19 2020;doi:10.1016/s1473-3099(20)30232-2
- 223 8. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-
- 224 nCoV) by real-time RT-PCR. Euro Surveill. Jan 2020;25(3)doi:10.2807/1560-
- 225 7917.Es.2020.25.3.2000045
- 9. Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in Critically Ill Patients in the
- 227 Seattle Region Case Series. The New England journal of medicine. Mar 30
- 228 2020;doi:10.1056/NEJMoa2004500
- 229 10. Furukawa NW, Brooks JT, Sobel J. Evidence Supporting Transmission of Severe Acute
- 230 Respiratory Syndrome Coronavirus 2 While Presymptomatic or Asymptomatic. *Emerging*
- 231 infectious diseases. May 4 2020;26(7)doi:10.3201/eid2607.201595
- 232 11. La Scola B, Le Bideau M, Andreani J, et al. Viral RNA load as determined by cell culture
- as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. Eur
- 234 *J Clin Microbiol Infect Dis.* Jun 2020;39(6):1059-1061. doi:10.1007/s10096-020-03913-9
- 235 12. Wynants L, Van Calster B, Bonten MMJ, et al. Prediction models for diagnosis and
- prognosis of covid-19 infection: systematic review and critical appraisal. *Bmj.* Apr 7
- 237 2020;369:m1328. doi:10.1136/bmj.m1328




Figure 1: Lowess smoothing curve plotting length of stay (days) vs qPCR Ct value on admission

# Table 1: Characteristics of patients in the study

Variable		N	%
Gender	Male	215	71.0%
	Females	88	29.0%
Symptoms on Admission	Asymptomatic	266	87.8%
	Symptomatic	39	12.2%
Mode of Transmission	Local	194	64.0%
	Travel	109	36.0%
Nationality	Bahraini	177	58.4%
	Indian	89	29.4%
	Bangladeshi	19	6.3%
	Other	18	5.9%
Category of Ct values	Low : Ct<35	271	89.4%
	High : Ct>=35	32	10.6%
Variable	N	Mean	Range
Age (years)	303	37.1 ± 15.1	0 to 87
Ct value on Admission	303	$27.5 \pm 5.1$	14.8 to 39
Length of Stay (days) (Time to viral clearance in Days)	303	$11.3 \pm 5.07$	4 to 32

# Table 2: Regression analysis for length of stay using Ct value as a covariate

Multivariate regression output, Adjusted for Age and Gender Outcome: Length of Stay in Days						
		Standard				
Continuous covariate	Coefficient	Error	P value	95% Confidence Interval		
Ct value	-0.28	.056	< 0.001	-0.39 to -0.17		
Multivariate regression output, Adjusted for Age and Gender Outcome: Length of Stay in Days						
		Standard				
Categorical covariate	Coefficient	Error	P value	95% Confidence Interval		
Low Ct value (<35)	-	-	-			
High Ct value (≥35)	-3.9	0.94	< 0.001	-5.75 to -2.05		

## Table 3: Two sample t test comparing mean Ct values between symptomatic and asymptomatic

### individuals

Status	Mean Ct value	Standard Error	95% Confidence Interval
Asymptomatic	27.8	0.31	27.2 to 28.4
Symptomatic	25.5	0.82	23.9 to 27.8
Difference	2.3	0.88	0.6 to 4.0
P Value			0.01